Bicyclic oligopeptides
AssigneeBoehringer Ingelheim Pharma GmbH & Co. KG
InventorsOlivier Potterat, Ruediger Streicher, Klaus Wagner, Till Maurer, Juergen Mack, Stefan Peters
Life of this patent
Estimating the term…
Loading patent…
AssigneeBoehringer Ingelheim Pharma GmbH & Co. KG
InventorsOlivier Potterat, Ruediger Streicher, Klaus Wagner, Till Maurer, Juergen Mack, Stefan Peters
Estimating the term…
The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of: (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and (b) a second cyclic group which is formed by an amide bonding of an amino acid with the α-carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); and to the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.
A bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of
Dependencies are inferred from the claim text.